HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme

Antiviral Therapy

Volumn 14, Issue 4, 2009, Pages 523-531

  Orrell, Catherine ^a   Walensky, Rochelle P ^b,c   Losina, Elena ^b,c,d   Pitt, Jennifer ^a   Freedberg, Kenneth A ^b,c,d   Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS LAMIVUDINE; ETRAVIRINE; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ANTIBIOTIC RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COMMUNITY CARE; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENOTYPE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOUTH AFRICA; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 68549110310     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report June 2008. Geneva: World Health Organization 2008. (Accessed 5 August 2008.) Available from http://www.who.int/hiv/en/
2. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368: 505-510.
3. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 Revision (Updated 7 August 2006. Accessed 5 August 2008.) Available from http://www.who.int/hiv/pub/guidelines/adult/en/
4. Department of Health, Provincial Government of the Western Cape (ZA). Western Cape Prevention of Mother to Child Transmission Guidelines. Cape Gateway Government Information and Services 2008. (Accessed 24 September 2008.) Available from http://www.capegateway.gov.za/eng/directories/ services/11500/6389
5. World Health Organization, UNAIDS. Repofi on WHO/UNAIDS meeting on forecasting ARV needs up to 2010: 7-8 November 2005, Geneva. Draft, January 2006. Geneva: World Health Organization 2006.
6. National Department of Health (ZA). National antiretroviral treatment guidelines. 1st Fd. Cape Town: Jacana 2004. (Accessed August 2008.) Available from http://www.doh.gov.za/docs/factsheets/guidelines/ artguidelines04/intro.pdf
7. British HIV Association. BHIVA guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. (Accessed 5 August 2008.) Available from http://www.bhiva.org/cms1222226.asp
8. Harries AD, Nyangulu DS, Hargreaves NJ, Kaluwa O, Salaniponi FM. Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 2001; 358:410-414.
9. Pillay V, Ledwaba J, Hunt G, et al. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther 2008; 13 Suppl 2:101-107.
10. Doualla-Bell F, Avalos A, Brenner B, et al. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother 2006; 50:4182-4185.
11. Brenner BG, Oliveira M, Doualla-Bell F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006; 20:F9-F13.
12. Abecasis AB, Deforche K, Snoeck J, et al. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS 2005; 19:1799-1806.
13. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among patients accessing a community-based antiretroviral programme in South Africa: implications for programme design. AIDS 2005; 19:2141-2148.
14. Lawn SD, Myer L, Harling G, Orrell C, Bekker L-G, Wood R. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006, 43:770-776.
15. Orrell C, Harling G, Lawn SD, et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 2007; 12:83-88.
16. Handema R, Terunuma H, Kasolo F, et al. Prevalence of drug-resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1. AIDS Res Hum Retroviruses 2003; 19:1151-160.
17. Loemba H, Brenner B, Parniak MA, et al. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother 2002; 46:2087-2094.
18. Kantor R, Zijenah LS, Shafer RW, et al. HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy. AIDS Res Hum Retroviruses 2002; 18:1407-1413.
19. Bellocchi MC, Forbici F, Palombi L, et al. Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme. J Med Virol 2005; 76:452-458.
20. DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006; 20:1391-1399.
21. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008; 46:1589-1597.
22. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16:138-145.
23. Stanford University HIV Resistance Database. Genotypic resistance interpretation algorithm. Version 4.3.6. (Updated 5 February 2008.) Available from http://hivdb.stanford.edu/pages/algs/HIVdb.html
24. van Harmelen J. Wood R, Lambrick M, Rybicki EP, Williamson AL, Williamson C. An association between HIV-1 subtype and mode of transmission in Cape Town, South-Africa. AIDS 1997; 11:81-88.
25. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W. Prevalence and risk factors or developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine. J Clin Virol 2008; 41:310-313.
26. Sungkanupartph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for H1V type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 20071, 44:447-452.
27. Bannister WP, Ruiz L, Cozzi-Lepri A, et al. Comparison, of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSlDA. AIDS 2008; 22:367-376.
28. Velazquez-Campoy A, Todd MJ, Vega S, Freire E. Catalytic effect and vitality of HIV-1 proteases from African subtypes. Proc Natl Acad Sci U S A 2001; 98:6062-6069.
29. Shafer RW, Nguyen DP, Fessel J. Case files from Stanford University Medical Centre: drug resistance testing in previously untreated patients with HIV - knowing what to look for and choosing appropriate therapy. MedGenMed 2006; 8:32.
30. Ly JK, Margot NA, MacArthur HL, Hung M, Miller MD, White KL. The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65R+Ml84V. Antivir Chem Chemother 2007; 18:307-316.
31. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 celf count, or clinical observation alone: a computer simulation model. Lancet 2008; 371:1443-1451.